Table 3 Consensus regions of copy number gain. Names in bold indicate those genes that have been implicated in prostate cancer. The * symbol indicates the same candidate genes from HPIN.

1p

1p22.3 – p31.1

37.5%

IGFBP10

2q

2q24.3 – q31.1

25%

TLK1, ITGA6

7p

7p22.1

37.5%

NUDT1, PDGFA

7p15.1 – p15.3

25%

GPNMB, AHR

8q

8q21.11 – qter

>37.5%

PTK2, RAD21 , MLZE, WISP1, NOV , ENPP2, MYC, PSCA , PTP4A3, KCNK9, TPD52 , MMP16, NBS1 , FABP5 , E2F5, BAALC, EBAG9

12q

12q14.3 – q21.33

25%

MDM2

16p

16p12.3 – p13.13

37.5%

BFAR

20q

20q11.23 – q13.11

25%

MMP9 , C20ORF1, SRC , GHRH , E2F1 , DNLC2A, BASE, CDC91L1, WFDC2, SLPI, CYP24 , BMP7 , CSE1L

4q

4q34.1

25%

FAT, MORF4, CASP3

6q

6q16.3

37.5%

8p

8p11.23 – p23.3

>50%

SFRP1, NKX3A , TRIM35, REAM, RB1CC1, PDGFRL , FGL1, TNFRSF10B, LZTS1 , DLC1, MTSG1, TUSC3 , FLJ32642, MTSS1, PINX1, DEFB1, CSMD1

10q

10q23.1

25%

10q23.2 – q25.1

25%

PTEN , MXI1 , LGI1, PDCD4, LAPSER1 , RNF27, SUFU, CASP7, LIMAB1, NEURL

13q

13q13.1 – q14.13

RFP2, TSC22, DBM , DDX26, KCNRG

13q14.3

25%

DLEU2, DLEU1, CHC1L, FAM10A4, FKHR

16q

16q22.1 – qter

37.5%

TERF2, CDH1, DERPC, WWOX , OKL38, CBFA2T3, CDH13, WFDC1, MAF, FOXF1, MVD

18q

18q21.32 – q22.2

25%

PMAIP1

4p

4p13 – p15.1

25%

UCHL1, CD38

7p

7p22.1

50%

*

7q

7q11.23

50%

LIMK1 , CLDN4, HSPB1

7q31.1 – q31.33

25%

NRCAM, PTPRZ1, POT1

8q

8q21.11 – qter

>50%

*

16p

16p12.2 – p13.13

25%

*

19p

19p13.11 – pter

25%

VAV1, RAB3D, ELAVL1, JUN-B, JUN-D, EPOR , DRIL1, BSG, ANGPTL4

1p

1p22.3

37.5%

1p13.1 – p13.2

25%

ST7L

5q

5q14.2 – q14.3

25%

6q

6q16.1

50%

8p

8p11.22 – p23.3

>50%

*

10q

10q22.2 – q23.33

>37.5%

UNC5B, BMPR1A, BLNK, PTEN

10q25.3 – q26.11

37.5%

DMBT1, TACC2, WDR11, FGFR2, DEC, BCCIP

12p

12p13.2

25%

CD9

13q

13q13.3 – q26.11

>50%

BRCA3, KLF5 *

16q

16q24.1 – qter

37.5%

*

18q

18q21.33 – q22.1

25%

*